Otonomy to Present at the J.P. Morgan Healthcare Conference
January 03, 2017 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Jan. 03, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy Appoints Kathie M. Bishop, Ph.D., as Chief Scientific Officer
November 30, 2016 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Nov. 30, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy to Present at Piper Jaffray Healthcare Conference
November 22, 2016 16:05 ET
|
Otonomy, Inc.
SAN DIEGO, Nov. 22, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy Reports Third Quarter 2016 Financial Results and Provides Corporate Update
November 03, 2016 16:13 ET
|
Otonomy, Inc.
SAN DIEGO, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy Announces Assignment of J Code for OTIPRIO®
November 02, 2016 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Nov. 02, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy to Report Third Quarter 2016 Financial Results and Provide Corporate Update
October 27, 2016 16:05 ET
|
Otonomy, Inc.
SAN DIEGO, Oct. 27, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy Holds Investor and Analyst Day and Provides Corporate Update
October 07, 2016 08:00 ET
|
Otonomy, Inc.
SAN DIEGO, Oct. 07, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy Successfully Completes Phase 2 Clinical Trial of OTIPRIO® in Pediatric Patients with Acute Otitis Media with Tympanostomy Tubes
October 04, 2016 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Oct. 04, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy Successfully Completes Open-Label Clinical Trial for OTIPRIO® in Patients with History of Otitis Media Requiring Tympanostomy Tubes
September 15, 2016 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Sept. 15, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy Announces OTIPRIO® Data Presentation and Symposium at American Academy of Otolaryngology - Head and Neck Surgery Foundation Annual Meeting
September 13, 2016 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Sept. 13, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...